For sufferers with estrogen receptor (ER)-positive, human epidermal progress issue receptor 2 (HER2)-negative superior breast most cancers, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, results in considerably longer progression-free survival in sufferers with ESR1 mutations, in response to a examine revealed on-line Could 31 within the New England Journal of Medication. The analysis was offered to coincide with the annual assembly of the American Society of Scientific Oncology, held from Could 31 to June 4 in Chicago.
Mario Campone, M.D., Ph.D., from the Institut de Cancérologie de l’Ouest Angers-Nantes in Saint-Herblain, France, and colleagues performed a section 3, open-label, randomized trial involving sufferers with ER-positive, HER2-negative superior breast most cancers who had acquired one earlier line of cyclin-dependent kinase 4 and 6 inhibitor remedy plus one line of endocrine remedy. Sufferers had been randomly assigned to obtain vepdegestrant at a dose of 200 mg orally as soon as every single day of every 28-day cycle or fulvestrant at a dose of 500 mg on day 1 and day 15 of cycle 1 and on day 1 of subsequent cycles (313 and 311 sufferers, respectively).
The researchers discovered that median progression-free survival was 5.0 and a pair of.1 months with vepdegestrant and fulvestrant, respectively, among the many 270 sufferers with ESR1 mutations (hazard ratio, 0.58). Median progression-free survival was 3.8 and three.6 months with vepdegestrant and fulvestrant, respectively, amongst all sufferers. In 23.4% and 17.6% of the sufferers within the vepdegestrant and fulvestrant teams, respectively, hostile occasions of grade 3 or larger occurred; hostile occasions resulting in discontinuation occurred in 2.9% and 0.7%, respectively.
“Additional follow-up is needed to further characterize the long-term efficacy and safety of vepdegestrant in this population,” the authors write.
The examine was funded by Pfizer, which is growing vepdegestrant.
Extra info:
Mario Campone et al, Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Superior Breast Most cancers, New England Journal of Medication (2025). DOI: 10.1056/NEJMoa2505725
Extra Data
Quotation:
ASCO: Vepdegestrant ups survival in ER+, HER2− superior breast most cancers with ESR1 mutations (2025, June 2)
retrieved 2 June 2025
from https://medicalxpress.com/information/2025-06-asco-vepdegestrant-ups-survival-er.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
